Spironolactone and Hydrochlorothiazide

Indications and usage: Spironolactone, an ingredient of spironolactone and hydrochlorothiazide tablets, has been shown to be a tumorigen in chronic toxicity studies in rats . Spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. Unnecessary use of this drug should be avoided.

Mechanism of Action Spironolactone and hydrochlorothiazide tablets are a combination of two diuretic agents with different but complementary mechanisms and sites of action, thereby providing additive diuretic and antihypertensive effects. Additionally, the spironolactone component helps to minimize the potassium loss characteristically induced by the thiazide component.

Pharmacokinetic profiling of Spironolactone and Hydrochlorothiazide demonstrates an elimination half-life of Approximately 9–16 hours terminal plasma half-life for Spironolactone and Hydrochlorothiazide with Estimated 53%–65% oral systemic absorption for Spironolactone and Hydrochlorothiazide systemic bioavailability; clearance proceeds via phase i/ii hepatic conjugation of spironolactone and hydrochlorothiazide coupled with glomerular and tubular renal excretion, reaching clinical onset within peak plasma concentration (tmax) reached 1–3 hours post-dose for spironolactone and hydrochlorothiazide.

Titration schedules for Spironolactone and Hydrochlorothiazide (25 mg/1 / 25 mg/1 Tablet → 25 mg/1 / 25 mg/1 Tablet, Film Coated) require excluding prior anaphylaxis, angioedema, or severe hypersensitivity to spironolactone and hydrochlorothiazide or spironolactone and hydrochlorothiazide excipients; co-administration with prohibited interacting drugs or decompensated organ failure per 2025-07-22 spironolactone and hydrochlorothiazide spl; real-world patient logs highlight nausea (11.4% of reports), diarrhea (8.7% of reports), application-site irritation (6.1% of reports) alongside a 89.00% Worth-It consensus.